Table 2.

Summary of trials combining endocrine therapy with PI3K inhibitors in patients with metastatic hormone receptor-positive breast cancer

Agent	ET	Setting	Trial
Alpelisib	Fulvestrant	After progression on AI	SOLAR-1; NCT02437318
Buparlisib	Fulvestrant	After progression on AI	BELLE-2; NCT01610284
Buparlisib	Fulvestant	After progression on mTOR inhibitor	BELLE-3; NCT01633060
Pictilisib	Fulvestrant	After progression on AI	FERGI; NCT01437566
Pictilisib + Palbociclib	Fulvestrant	After progression on AI	PASTOR; NCT02599714
Gedatolisib + Palbociclib	Fulvestrant or Letrozole	3 arms: • No prior endocrine therapy • Progression on or after 1 line of endocrine therapy, no prior CDK inhibitor therapy • Progression after 1 or 2 prior endocrine therapies, following prior CDK inhibitor therapy	NCT02684032

ET endocrine therapy, AI aromatase inhibitor